These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 7626453)

  • 1. A molecular model for the interaction between vorozole and other non-steroidal inhibitors and human cytochrome P450 19 (P450 aromatase).
    Koymans LM; Moereels H; Vanden Bossche H
    J Steroid Biochem Mol Biol; 1995 Jun; 53(1-6):191-7. PubMed ID: 7626453
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Aromatase inhibitors--mechanisms for non-steroidal inhibitors.
    Vanden Bossche HV; Moereels H; Koymans LM
    Breast Cancer Res Treat; 1994; 30(1):43-55. PubMed ID: 7949204
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of the mechanism of aromatase cytochrome P450. A site-directed mutagenesis study.
    Kao YC; Korzekwa KR; Laughton CA; Chen S
    Eur J Biochem; 2001 Jan; 268(2):243-51. PubMed ID: 11168357
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Vorozole, a specific non-steroidal aromatase inhibitor.
    Wouters W; Snoeck E; De Coster R
    Breast Cancer Res Treat; 1994; 30(1):89-94. PubMed ID: 7726994
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Binding characteristics of aromatase inhibitors and phytoestrogens to human aromatase.
    Chen S; Kao YC; Laughton CA
    J Steroid Biochem Mol Biol; 1997 Apr; 61(3-6):107-15. PubMed ID: 9365179
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mutagenesis study at a postulated hydrophobic region near the active site of aromatase cytochrome P450.
    Zhou D; Cam LL; Laughton CA; Korzekwa KR; Chen S
    J Biol Chem; 1994 Jul; 269(30):19501-8. PubMed ID: 8034720
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Three-dimensional model of cytochrome P450 human aromatase.
    Loge C; Le Borgne M; Marchand P; Robert JM; Le Baut G; Palzer M; Hartmann RW
    J Enzyme Inhib Med Chem; 2005 Dec; 20(6):581-5. PubMed ID: 16408794
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibition of the in vivo conversion of androstenedione to estrone by the aromatase inhibitor vorozole in healthy postmenopausal women.
    van der Wall E; Donker TH; de Frankrijker E; Nortier HW; Thijssen JH; Blankenstein MA
    Cancer Res; 1993 Oct; 53(19):4563-6. PubMed ID: 8402628
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of androgens on aromatase activity and 11C-vorozole binding in granulosa cells in vitro.
    Kirilovas D; Naessen T; Bergström M; Bonasera TA; Bergström-Pettermann E; Holte J; Carlström K; Simberg N; Långström B
    Acta Obstet Gynecol Scand; 2003 Mar; 82(3):209-15. PubMed ID: 12694114
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Characterization of stable human aromatase expressed in E. coli.
    Kagawa N; Hori H; Waterman MR; Yoshioka S
    Steroids; 2004 Apr; 69(4):235-43. PubMed ID: 15183689
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Functional domains of human aromatase cytochrome P450 characterized by linear alignment and site-directed mutagenesis.
    Amarneh B; Corbin CJ; Peterson JA; Simpson ER; Graham-Lorence S
    Mol Endocrinol; 1993 Dec; 7(12):1617-24. PubMed ID: 8145767
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular modelling study of the binding of inhibitors of aromatase to the cytochrome P-450 heme.
    Ahmed S; Davis PJ; Owen CP
    Drug Des Discov; 1996 Oct; 14(2):91-102. PubMed ID: 9010616
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Direct spectroscopic evidence for binding of anastrozole to the iron heme of human aromatase. Peering into the mechanism of aromatase inhibition.
    Maurelli S; Chiesa M; Giamello E; Di Nardo G; Ferrero VE; Gilardi G; Van Doorslaer S
    Chem Commun (Camb); 2011 Oct; 47(38):10737-9. PubMed ID: 21858332
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vitro kinetic properties of the Thr201Met variant of human aromatase gene CYP19A1: functional responses to substrate and product inhibition and enzyme inhibitors.
    Payne EJ; Ingley E; Dick IM; Wilson SG; Bond CS; Prince RL
    J Clin Endocrinol Metab; 2009 Aug; 94(8):2998-3002. PubMed ID: 19470632
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Discovery of a novel class of aldol-derived 1,2,3-triazoles: potent and selective inhibitors of human cytochrome P450 19A1 (aromatase).
    McNulty J; Nair JJ; Vurgun N; Difrancesco BR; Brown CE; Tsoi B; Crankshaw DJ; Holloway AC
    Bioorg Med Chem Lett; 2012 Jan; 22(1):718-22. PubMed ID: 22079757
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Vorozole.
    Wiseman LR; Spencer CM
    Drugs Aging; 1997 Sep; 11(3):245-50; discussion 251-2. PubMed ID: 9303282
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Aromatase inhibitors].
    Feutrie ML; Bonneterre J
    Bull Cancer; 1999 Oct; 86(10):821-7. PubMed ID: 10572233
    [TBL] [Abstract][Full Text] [Related]  

  • 18. 1-[(Benzofuran-2-yl)phenylmethyl]-triazoles and -tetrazoles - potent competitive inhibitors of aromatase.
    Vinh TK; Ahmadi M; Delgado PO; Perez SF; Walters HM; Smith HJ; Nicholls PJ; Simons C
    Bioorg Med Chem Lett; 1999 Jul; 9(14):2105-8. PubMed ID: 10450990
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Binding characteristics of seven inhibitors of human aromatase: a site-directed mutagenesis study.
    Kao YC; Cam LL; Laughton CA; Zhou D; Chen S
    Cancer Res; 1996 Aug; 56(15):3451-60. PubMed ID: 8758911
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effector role of cytochrome P450 reductase for androstenedione binding to human aromatase.
    Zhang C; Catucci G; Di Nardo G; Gilardi G
    Int J Biol Macromol; 2020 Dec; 164():510-517. PubMed ID: 32698066
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.